00:36 , Oct 19, 2018 |  BC Innovations  |  Tools & Techniques

Allogeneic CARs on the horizon

With the first generation of autologous, personalized CAR T cell therapies on the market, the field is turning to allogeneic technologies to provide better scale and lower costs. But drug makers are learning that as...
16:43 , Sep 21, 2018 |  BC Week In Review  |  Clinical News

Eureka's ET140202 leads to tumor regression in Phase I for HCC

Eureka Therapeutics Inc. (Emeryville, Calif.) said ET140202 led to one case of complete tumor regression and two cases of partial tumor regression in six evaluable patients with alpha fetoprotein (AFP)-positive hepatocellular carcinoma (HCC) in a...
20:04 , Aug 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Alt-neoantigens

Neoantigens derived from alternative splicing could broaden the target space for cancer vaccines and T cell therapies, according to two studies published this month. While questions remain about whether they are sufficiently immunogenic to create...
15:35 , Jul 27, 2018 |  BC Week In Review  |  Company News

Sangamo acquiring TxCell, accelerates CAR Treg development

Sangamo Therapeutics Inc. (NASDAQ:SGMO) will acquire CAR Treg therapy company TxCell S.A. (Euronext:TXCL), accelerating its immunology strategy by two years, according to a presentation on July 23. Sangamo expects to be the first company to...
22:49 , Jul 23, 2018 |  BC Extra  |  Company News

Sangamo acquiring TxCell, accelerates CAR Treg development

Sangamo Therapeutics Inc. (NASDAQ:SGMO) will acquire CAR Treg therapy company TxCell S.A. (Euronext:TXCL), accelerating its immunology strategy by two years, according to a presentation on Monday. Sangamo expects to be the first company to bring...
15:40 , Jul 12, 2018 |  BC Innovations  |  Translation in Brief

Reviving NK cells

Researchers from the University of Science and Technology of China have identified a key role for TIGIT in NK cell exhaustion that suggests immunotherapies targeting TIGIT may be useful against cancers that have failed to...
19:41 , Apr 12, 2018 |  BC Innovations  |  Translation in Brief

Shape recognition

A Cardiff University team has engineered a D-peptide that mimicked the T cell agonist activity of an influenza peptide and protected mice from infection by the virus. The findings suggest oral vaccines based on synthetic...
18:16 , Apr 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Influenza virus Mouse studies suggest a vaccine based on an M1-mimicking synthetic peptide could help treat influenza. Screening of a combinatorial library of D-peptides against CD8 + T cell clones specific for the immunodominant...
23:51 , Mar 19, 2018 |  BC Innovations  |  Translation in Brief

Crafting CAR Tregs

TxCell S.A. (Euronext:TXCL) thinks it has cracked the code on building CAR Tregs without running into the manufacturing challenges that can compromise the cells’ immunosuppressive function. The company presented data on their manufacturing process at...
19:31 , Jan 24, 2018 |  BC Innovations  |  Emerging Company Profile

D over L for diabetes

ImmunoMolecular Therapeutics LLC’s small molecule inhibitor of an HLA-DQ8 peptide could treat Type I diabetes without courting the broad-spectrum immunosuppression of other disease-modifying therapies in development. About 60% of Type I diabetes patients carry the...